Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | CASP6 | P55212 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.34 |
| ▸ | CASP1 | P29466 | 2/20 | 0.34 |
| ▸ | HTT | P42858 | 2/20 | 0.34 |
| ▸ | CASP7 | P55210 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.34 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13182189 | 0.76 | ALDH1A1 (0.48) | ALDH1A1NPC1POLBRAB9AKDM4E | |
| SCHEMBL20272946 | 0.72 | ALDH1A1 (0.44) | ALDH1A1NPC1POLBRAB9AKDM4E | |
| SCHEMBL483352 | 0.72 | PI4KA (0.46) | ALDH1A1NPC1RAB9AKDM4EMEN1 | |
| SCHEMBL17265834 | 0.71 | ALDH1A1 (0.37) | ALDH1A1NPC1RAB9AKDM4EHSD17B10 | |
| SCHEMBL832575 | 0.71 | ALDH1A1 (0.48) | ALDH1A1NPC1POLBRAB9AKDM4E | |
| SCHEMBL29384237 | 0.71 | ALDH1A1 (0.48) | ALDH1A1NPC1POLBRAB9AKDM4E | |
| SCHEMBL997757 | 0.71 | ALDH1A1 (0.54) | ALDH1A1NPC1POLBRAB9AKDM4E | |
| SCHEMBL28910441 | 0.71 | ALDH1A1 (0.48) | ALDH1A1NPC1POLBRAB9AKDM4E | |
| SCHEMBL29393471 | 0.70 | — | — | |
| SCHEMBL12820 | 0.70 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 540 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10071156-B2 | Aqueous gel formulations containing immune response modifiers | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2018-09-11 | — | — | US | claimed |
| US-20160101173-A1 | AQUEOUS GEL FORMULATIONS CONTAINING IMMUNE RESPONSE MODIFIERS | 3M INNOVATIVE PROPERTIES CO (US) | 2016-04-14 | — | — | US | claimed |
| US-9248127-B2 | Aqueous gel formulations containing immune response modifiers | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2016-02-02 | — | — | US | claimed |
| US-20120237551-A1 | IMMUNE RESPONSE MODIFIER FORMULATIONS CONTAINING OLEIC ACID AND METHODS | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2012-09-20 | — | — | US | claimed |
| EP-1651190-B1 | FORMULATIONS CONTAINING AN IMMUNE RESPONSE MODIFIER | 3M INNOVATIVE PROPERTIES CO (US) | 2012-09-19 | — | — | EP | claimed |
| US-7923560-B2 | Associated with typically attached to and, preferably, covalently attached to macromolecular support, e.g. a gel, foam, sponge, fiber, hydrogel, and a bead.; controlled drug delivery; retension of localized biological activity; toll-like receptors agonists to induce cytokine and interferon synthesis | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2011-04-12 | — | — | US | claimed |
| EP-1651190-A4 | FORMULATIONS CONTAINING AN IMMUNE RESPONSE MODIFIER | 3M INNOVATIVE PROPERTIES CO (US) | 2009-07-15 | — | — | EP | claimed |
| US-20090163532-A1 | Aqueous Gel Formulations Containing Immune Response Modifiers | COLEY PHARMACEUTICAL GROUP, INC. (US) | 2009-06-25 | — | — | US | claimed |
| EP-1735010-A4 | METHODS, COMPOSITIONS, AND PREPARATIONS FOR DELIVERY OF IMMUNE RESPONSE MODIFIERS | 3M INNOVATIVE PROPERTIES CO (US) | 2008-08-27 | — | — | EP | claimed |
| WO-2008082381-A1 | IMMUNE RESPONSE MODIFIER FORMULATIONS CONTAINING OLEIC ACID AND METHODS | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2008-07-10 | — | — | WO | claimed |
| WO-2005016275-A2 | FORMULATIONS CONTAINING AN IMMUNE RESPONSE MODIFIER | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2005-02-24 | — | — | WO | claimed |
| WO-2005001022-A2 | METHODS AND COMPOSITIONS FOR ENHANCING IMMUNE RESPONSE | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2005-01-06 | — | — | WO | claimed |
| US-20040265351-A1 | Methods and compositions for enhancing immune response | 3M INNOVATIVE PROPERTIES COMPANY | 2004-12-30 | — | — | US | claimed |
| US-20040258698-A1 | Delivery of immune response modifier compounds | 3M INNOVATIVE PROPERTIES COMPANY | 2004-12-23 | — | — | US | claimed |
| WO-2004108072-A2 | DELIVERY OF IMMUNE RESPONSE MODIFIER COMPOUNDS USING METAL-CONTAINING PARTICULATE SUPPORT MATERIALS | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2004-12-16 | — | — | WO | claimed |
| WO-2004091500-A2 | DELIVERY OF IMMUNE RESPONSE MODIFIER COMPOUNDS | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2004-10-28 | — | — | WO | claimed |
| US-20040202720-A1 | Delivery of immune response modifier compounds using metal-containing particulate support materials | 3M INNOVATIVE PROPERTIES COMPANY | 2004-10-14 | — | — | US | claimed |
| EP-1450804-A1 | PHARMACEUTICAL FORMULATIONS COMPRISING AN IMMUNE RESPONSE MODIFIER | 3M Innovative Properties Company (US) | 2004-09-01 | — | — | EP | claimed |
| US-20030199538-A1 | Pharmaceutical formulation comprising an immune response modifier | 3M INNOVATIVE PROPERTIES COMPANY | 2003-10-23 | — | — | US | claimed |
| WO-2003045391-A1 | PHARMACEUTICAL FORMULATIONS COMPRISING AN IMMUNE RESPONSE MODIFIER | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2003-06-05 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040265351-A1 | Methods and compositions for enhancing immune response | LRBA, CD69, MYD88 | RIPK1 1547/4885ALDH1A1 3930/4885NPC1 1296/4885 |
| US-20030199538-A1 | Pharmaceutical formulation comprising an immune response modifier | ICOS, STAT6, INMT | RIPK1 3060/4885ALDH1A1 649/4885NPC1 4144/4885 |
| US-20040258698-A1 | Delivery of immune response modifier compounds | MIF, IRF3, CLEC4M | RIPK1 1209/4885ALDH1A1 3449/4885NPC1 3551/4885 |
| US-10071156-B2 | Aqueous gel formulations containing immune response modifiers | IFNG, ICOS, IL4 | RIPK1 1412/4885ALDH1A1 2347/4885NPC1 4682/4885 |
| US-20090163532-A1 | Aqueous Gel Formulations Containing Immune Response Modifiers | IFNG, ICOS, IL4 | RIPK1 1412/4885ALDH1A1 2347/4885NPC1 4682/4885 |
| US-20160101173-A1 | AQUEOUS GEL FORMULATIONS CONTAINING IMMUNE RESPONSE MODIFIERS | IFNG, ICOS, IL4 | RIPK1 1412/4885ALDH1A1 2347/4885NPC1 4682/4885 |
| US-20040202720-A1 | Delivery of immune response modifier compounds using metal-containing particulate support materials | MIF, IRF3, IRF2BP2 | RIPK1 1139/4885ALDH1A1 4306/4885NPC1 3559/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.